SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2019
This trial will evaluate the addition of cytoreductive stereotactic body radiation therapy (SBRT) to standard of care combination ipilimumab and nivolumab (I/N) versus I/N alone for the treatment of metastatic kidney cancer.
Epistemonikos ID: e2f79d840dcb5e58ec5515bc2591112c57c2bfb5
First added on: Dec 20, 2022